KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 120 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $39,000 | -17.0% | 11,563 | -7.1% | 0.00% | – |
| Q2 2018 | $47,000 | 0.0% | 12,450 | +8.8% | 0.00% | – |
| Q1 2018 | $47,000 | -24.2% | 11,448 | -13.9% | 0.00% | – |
| Q4 2017 | $62,000 | -16.2% | 13,296 | +4.8% | 0.00% | -100.0% |
| Q4 2016 | $74,000 | +25.4% | 12,682 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $59,000 | -22.4% | 12,682 | -15.9% | 0.00% | 0.0% |
| Q4 2015 | $76,000 | -41.5% | 15,081 | +15.4% | 0.00% | -50.0% |
| Q2 2015 | $130,000 | -47.8% | 13,073 | -33.1% | 0.00% | -33.3% |
| Q1 2015 | $249,000 | -10.4% | 19,541 | -0.5% | 0.00% | 0.0% |
| Q4 2014 | $278,000 | -44.4% | 19,640 | -45.9% | 0.00% | -57.1% |
| Q3 2014 | $500,000 | -27.0% | 36,332 | -18.5% | 0.01% | -22.2% |
| Q2 2014 | $685,000 | -55.5% | 44,567 | -50.7% | 0.01% | -52.6% |
| Q1 2014 | $1,539,000 | +195.4% | 90,330 | +75.0% | 0.02% | +58.3% |
| Q3 2013 | $521,000 | +31.6% | 51,623 | -2.6% | 0.01% | +50.0% |
| Q2 2013 | $396,000 | – | 52,990 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management I, LLC | 1,312,006 | $22,357,000 | 15.70% |
| VHCP Management, LLC | 1,000,273 | $17,045,000 | 8.86% |
| HARVEY CAPITAL MANAGEMENT INC | 915,800 | $15,605,000 | 6.22% |
| Baupost Group | 6,310,850 | $107,537,000 | 2.60% |
| SECTORAL ASSET MANAGEMENT INC | 3,537,590 | $60,281,000 | 2.48% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 587,504 | $10,011,000 | 2.31% |
| Knoll Capital Management, LLC | 200,000 | $3,408,000 | 1.76% |
| Camber Capital Management LP | 1,250,000 | $21,300,000 | 1.67% |
| NORTHPOINTE CAPITAL LLC | 877,875 | $14,958,000 | 1.52% |
| DAFNA Capital Management LLC | 100,000 | $1,704,000 | 1.46% |